^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ZG006
i
Other names: ZG006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Suzhou Zelgen
Drug class:
CD3 agonist, DLL3 inhibitor
Related drugs:
2ms
A Phase 1 Dose Escalation Study of ZG006 in Patients with Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1 trial
|
ZG006
6ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=78, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial • Metastases
|
ZG006
9ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=105, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
ZG006
1year
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=54, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
ZG006
over1year
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=54, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
ZG006
Share via
